These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 10465063)

  • 1. Management of hypertension: the advent of a new angiotensin II receptor antagonist.
    Hedner T
    J Hypertens Suppl; 1999 Jun; 17(2):S21-5. PubMed ID: 10465063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical profile of the angiotensin II receptor blocker eprosartan.
    Hedner T
    J Hypertens Suppl; 2002 Jun; 20(5):S33-8. PubMed ID: 12184062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological mechanism of angiotensin II receptor antagonists: implications for the treatment of elevated systolic blood pressure.
    Brooks DP; Ruffolo RR
    J Hypertens Suppl; 1999 Jun; 17(2):S27-32. PubMed ID: 10465064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension.
    Levine B
    Curr Med Res Opin; 2001; 17(1):8-17. PubMed ID: 11464450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction.
    de la Sierra A; Ram CV
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S1-3. PubMed ID: 18093407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of eprosartan, a new angiotensin II receptor blocker.
    Shusterman NH
    Am Heart J; 1999 Sep; 138(3 Pt 2):238-45. PubMed ID: 10467219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update on non-peptide angiotensin receptor antagonists and related RAAS modulators.
    Aulakh GK; Sodhi RK; Singh M
    Life Sci; 2007 Aug; 81(8):615-39. PubMed ID: 17692338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin II type 1 receptor blockade: a novel therapeutic concept.
    Johnston CI
    Blood Press Suppl; 2000; 1():9-13. PubMed ID: 11059629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy.
    Suzuki H; Kanno Y; Kaneko K; Kaneko M; Kotaki S; Mimura T; Takane H
    Ther Apher Dial; 2004 Aug; 8(4):320-7. PubMed ID: 15274684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension.
    Delles C; Jacobi J; John S; Fleischmann I; Schmieder RE
    Kidney Int; 2002 Apr; 61(4):1462-8. PubMed ID: 11918753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AT1 antagonism by eprosartan lowers heart rate variability and baroreflex gain.
    Heusser K; Vitkovsky J; Schmieder RE; Schobel HP
    Auton Neurosci; 2003 Aug; 107(1):45-51. PubMed ID: 12927226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects.
    Murdoch DR; McDonagh TA; Farmer R; Morton JJ; McMurray JJ; Dargie HJ
    Am Heart J; 2001 May; 141(5):800-7. PubMed ID: 11320369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline.
    Ram CV; Rudmann MA
    Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1003-11. PubMed ID: 18035916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential of the angiotensin II receptor 1 blocker eprosartan in the management of patients with hypertension or heart failure.
    Hollenberg NK
    Curr Hypertens Rep; 2001 Sep; 3 Suppl 1():S25-8. PubMed ID: 11580885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Stress-associated hypertension in the work place: results of the STARLET project].
    Lüders S; Hammersen F; Kulschewski A; Frerichs A; Frieg R; Hahnheiser D; Reich G; Schnieders M; Schrandt G; Schrader J
    Dtsch Med Wochenschr; 2006 Nov; 131(46):2580-5. PubMed ID: 17096303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical profile of eprosartan.
    Puig JG; López MA; Bueso TS; Bernardino JI; Jiménez RT;
    Cardiovasc Drugs Ther; 2002 Dec; 16(6):543-9. PubMed ID: 12766389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ACE inhibitors versus AT1 blockers in the treatment of hypertension and syndrome X.
    Feldman R
    Can J Cardiol; 2000 Aug; 16 Suppl E():41E-44E. PubMed ID: 10906626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological properties of angiotensin II receptor antagonists.
    Timmermans PB
    Can J Cardiol; 1999 Nov; 15 Suppl F():26F-8F. PubMed ID: 10579749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.